PERSONAL COVID-BP
Full Title: Personalised Electronic Record Supported Optimisation when Alone for Patients with Hypertension – Pilot Study for Remote Medical Management of Hypertension During the COVID-19 Pandemic
Short Title: PERSONAL COVID BP
Sponsor: Queen Mary University of London
Funder: INNOVATE-UK, Closed Loop Medicine Ltd
Chief Investigator: Dr David Collier, Research Fellow and Joint Clinical Director of the William Harvey Research Institute Clinical Research Centre
Co-Investigators: Rebecca James, Study Coordinator, Queen Mary University of London
Contact: d.j.collier@qmul.ac.uk
Registration: https://www.clinicaltrials.gov/study/NCT04559074
Study Design: Pilot community-based randomised trial with remote monitoring
Objectives:
- To evaluate a remote clinical care model for hypertension management using personalised medicine and telemonitoring during the COVID-19 pandemic
- To test the feasibility of optimising blood pressure management using a digital platform supported by clinical teleconsultation
Number of Participants: 1000
Devices Used: Electronic diary platform; teleconsultation tools
Study Duration: 3 months
Location: William Harvey Research Institute (Remote)
Summary: This community-based pilot study was developed during the COVID-19 pandemic to assess the feasibility of remote hypertension management using digital tools and personalised medication support. Participants were randomised into two groups, both of which used an electronic diary to record blood pressure and COVID-19 symptoms over a 3-month period.
One group also received a study medication, amlodipine, with personalised dose adjustments to achieve optimal blood pressure control. Both groups had scheduled teleconsultations with study clinicians, and the study was conducted entirely remotely. The intervention aimed to support patients with essential hypertension in managing their condition safely while reducing the need for in-person healthcare contact during the pandemic.
Participants were aged 18 and over, with no upper age limit, and had a confirmed diagnosis of essential hypertension. The trial concluded in December 2021 and contributed to understanding how remote care and digital health tools could be leveraged in managing chronic conditions like hypertension.